WallStreetZenWallStreetZen

NASDAQ: DSGN
Design Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DSGN

Based on 5 analysts offering 12 month price targets for Design Therapeutics Inc

Min Forecast
$14.00+26.13%
Avg Forecast
$16.40+47.75%
Max Forecast
$21.00+89.19%

Should I buy or sell DSGN stock?

Based on 5 analysts offering ratings for Design Therapeutics Inc.

Buy
Strong Buy
1 analysts 20%
Buy
4 analysts 80%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DSGN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates DSGN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their DSGN stock forecasts and price targets.

DSGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-04
lockedlocked$00.00+00.00%2026-03-16
lockedlocked$00.00+00.00%2026-03-10
lockedlocked$00.00+00.00%2026-01-07
lockedlocked$00.00+00.00%2025-12-03

1 of 1

Forecast return on equity

Is DSGN forecast to generate an efficient return?

Company
-53.03%
Industry
85.39%
Market
170.3%
DSGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DSGN forecast to generate an efficient return on assets?

Company
-50.18%
Industry
29.6%
DSGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DSGN earnings per share forecast

What is DSGN's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$1.39
Avg 2 year Forecast
-$1.63
Avg 3 year Forecast
-$1.93

DSGN revenue forecast

What is DSGN's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$8.7M

DSGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DSGN$11.10$16.40+47.75%Buy
BBOT$8.81$24.00+172.42%Strong Buy
ANRO$20.78$35.33+70.03%Strong Buy
ALLO$1.90$8.54+349.42%Strong Buy
KZIA$12.97$21.50+65.77%Strong Buy
View Top Biotech Stocks

Design Therapeutics Stock Forecast FAQ

Is Design Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: DSGN) stock is to Buy DSGN stock.

Out of 5 analysts, 1 (20%) are recommending DSGN as a Strong Buy, 4 (80%) are recommending DSGN as a Buy, 0 (0%) are recommending DSGN as a Hold, 0 (0%) are recommending DSGN as a Sell, and 0 (0%) are recommending DSGN as a Strong Sell.

If you're new to stock investing, here's how to buy Design Therapeutics stock.

What is DSGN's earnings growth forecast for 2026-2028?

(NASDAQ: DSGN) Design Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.32%.

Design Therapeutics's earnings in 2026 is -$69,713,000.On average, 9 Wall Street analysts forecast DSGN's earnings for 2026 to be -$86,640,314, with the lowest DSGN earnings forecast at -$99,768,770, and the highest DSGN earnings forecast at -$76,728,393. On average, 9 Wall Street analysts forecast DSGN's earnings for 2027 to be -$101,929,782, with the lowest DSGN earnings forecast at -$114,458,651, and the highest DSGN earnings forecast at -$88,532,761.

In 2028, DSGN is forecast to generate -$120,660,628 in earnings, with the lowest earnings forecast at -$179,951,033 and the highest earnings forecast at -$89,188,559.

What is DSGN's revenue growth forecast for 2026-2028?

(NASDAQ: DSGN) Design Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.73%.

Design Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast DSGN's revenue for 2026 to be $0, with the lowest DSGN revenue forecast at $0, and the highest DSGN revenue forecast at $0. On average, 7 Wall Street analysts forecast DSGN's revenue for 2027 to be $0, with the lowest DSGN revenue forecast at $0, and the highest DSGN revenue forecast at $0.

In 2028, DSGN is forecast to generate $541,501,965 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,573,915,745.

What is DSGN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DSGN) forecast ROA is -50.18%, which is lower than the forecast US Biotechnology industry average of 29.6%.

What is DSGN's Price Target?

According to 5 Wall Street analysts that have issued a 1 year DSGN price target, the average DSGN price target is $16.40, with the highest DSGN stock price forecast at $21.00 and the lowest DSGN stock price forecast at $14.00.

On average, Wall Street analysts predict that Design Therapeutics's share price could reach $16.40 by May 4, 2027. The average Design Therapeutics stock price prediction forecasts a potential upside of 47.75% from the current DSGN share price of $11.10.

What is DSGN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: DSGN) Design Therapeutics's current Earnings Per Share (EPS) is -$1.20. On average, analysts forecast that DSGN's EPS will be -$1.39 for 2026, with the lowest EPS forecast at -$1.60, and the highest EPS forecast at -$1.23. On average, analysts forecast that DSGN's EPS will be -$1.63 for 2027, with the lowest EPS forecast at -$1.83, and the highest EPS forecast at -$1.42. In 2028, DSGN's EPS is forecast to hit -$1.93 (min: -$2.88, max: -$1.43).

What is DSGN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DSGN) forecast ROE is -53.03%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.